Clinical Trial Update: ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial of ABBV-383 for relapsed or refractory Waldenström macroglobulinemia is listed and currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• ABBV-383 (Etentamig)

Snippet

Sponsor: Mayo Clinic | Conditions: Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING